The cost primer
An offer is easier to compare when every part of the cost is on the same page. Ask for the ongoing price as well as the opening offer.
A drug company’s self-pay offer is its price when you pay without using insurance.
As of September 26, 2026, drug-company cash offers for brand-name weight and diabetes medicines mostly run from about $149 to $499 a month.
Some prices are higher when a refill falls outside the offer’s time limit.
Offers can differ in which medicine you get, how much is in each dose and how long the supply lasts.
Compare the exact prescription and the offer’s written terms.
Give your insurance plan the medicine’s exact name and explain why it would be prescribed.
Your plan lists the drugs it covers in a document called a formulary.
With prior authorization, coverage needs the insurer’s agreement ahead of time.
Ask: What would I pay after any approval, and what happens if it is refused?
The maker’s published list price may differ from the amount you pay with cash, a discount card, insurance or a government program.
A copay is the share of a medicine’s cost you pay under a plan.
Ask: Which price applies to me, and what will I actually pay?
In the online weight-care pages checked September 26, 2026, membership fees were common and medicine was usually billed separately.
Is the quoted price an opening offer? Is there a joining charge or a payment due before the assessment?
What does a usual refill cost? Does the price change if I need a different amount in each dose? When does the offer end?
Are the visit, medicine, any tests, delivery and follow-up included? Ask for each item in writing.
How do I cancel? Does a longer commitment affect the total? What happens to a prepaid balance?
The September 26, 2026 check found that many cash offers and savings cards set December 31, 2026 as the end of their terms.
Ask for fresh terms when comparing a later refill.
Medicare program rules, checked September 26, 2026.
GLP-1 is a name used for medicines that help control blood sugar or weight, depending on the product.
Semaglutide is one example: its Wegovy brand is for weight control, while Ozempic is for type 2 diabetes.
Mounjaro is the tirzepatide brand for type 2 diabetes; for weight control, tirzepatide is sold as Zepbound.
The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027; eligible people pay $50 for a month’s supply of certain weight medicines.
Ask whether visits, tests or other care add charges beyond that $50 medicine payment.
Adults need an eligible Medicare drug plan, a prescription and approval for this program before it pays.
Body mass index (BMI) uses your height together with your weight to give a number for assessing weight.
Blood sugar above normal but below the diabetes level is called pre-diabetes.
For example, BMI of 35 or more satisfies the weight rule; pre-diabetes with BMI of at least 27 can meet it too.
Other health and plan rules still apply. Ask the person prescribing to calculate your BMI and check the full eligibility list with you.
Bridge payments are handled separately from your usual Medicare medicine coverage, called Part D.
Ask the person prescribing to request Bridge approval and check with your pharmacy how to fill through the program.
People with type 2 diabetes use their usual Medicare drug coverage instead of the Bridge.
A GLP-1 medicine payment made for you by Part D during 2026 rules out Bridge use for you that year.
Your usual coverage still depends on which drugs your plan covers and whether it approves the prescription.
Part D sets an annual limit on your spending for covered drugs; the $50 Bridge payments do not count toward it.
If you receive Bridge medicine every month for a year, you pay $600 in medicine charges outside that limit.
Read the Medicare Bridge rulesFDA, the Food and Drug Administration, maintains the national drug shortage list.
As of September 26, 2026, semaglutide injections and tirzepatide are absent from FDA’s national shortage list.
In compounding, a doctor or pharmacist prepares medicine to order rather than providing a drug that is already made.
Federal law limits how often and how much pharmacies or doctors may make versions that are essentially copies of medicines already available to buy.
Here, a copy means a pharmacy-made version of an available drug, rather than an FDA-approved generic.
A change made for you can fall outside that copy rule if the person prescribing decides it makes a significant medical difference for you.
For example, removing a dye you are allergic to may meet a medical need.
Paying less by itself does not qualify as that medical difference.
Ask why you need the pharmacy-made version, what would be changed and why that change matters for your health.
Next: check the offer for reasons to pause